Sumitomo Offers to Buy All of Myovant in $2.5 Billion Deal

Sumitomo Offers to Buy All of Myovant in $2.5 Billion Deal

Source: 
Yahoo/Bloomberg
snippet: 

A fully-owned subsidiary of Sumitomo Pharma Co. offered to buy the remaining outstanding shares of pharmaceutical company Myovant Sciences Ltd., seeking to bolster the development of drugs for women’s health and prostate cancer.